secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0001601830-24-000009
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion Pharmaceuticals amends bylaws to enhance proxy disclosure and conform to Delaware law
--------------------------------------------------------------------------------

- Bylaw amendments enhance procedural mechanics and disclosure for stockholder director nominations and proposals (except Rule 14a-8).
- Amendments incorporate universal proxy rules per Rule 14a-19 and conform to recent DGCL changes.
- Updated provisions regarding Board committees, officers, written consent, indemnification, and exclusive forum.
- Compensation recovery policy reflected in limitation on indemnification.
- Effective January 25, 2024; filed as Exhibit 3.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000009/0001601830-24-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000009/rxrx-20240125.htm
  HTML page:      https://secwatch.observer/filing/0001601830-24-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer